<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16461">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892591</url>
  </required_header>
  <id_info>
    <org_study_id>14-1909</org_study_id>
    <nct_id>NCT02892591</nct_id>
  </id_info>
  <brief_title>Cannabis Versus Oxycodone for Pain Relief</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Crossover Study Comparing the Analgesic Efficacy of Cannabis Versus Oxycodone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the ability of cannabis to reduce chronic back and neck pain and to
      reduce sensitivity to an acute painful stimulus. Cannabis will be compared to both oxycodone
      and a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates the ability of cannabis to reduce chronic back and neck pain and to
      reduce sensitivity to an acute painful stimulus. Cannabis will be compared to both oxycodone
      and a placebo.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Numeric Rating Scale (NRS) score (Spine Patients)</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Threshold (kPa) (Healthy Controls)</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change score</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug effect rating</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychoactive effect rating</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood rating</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wechsler Adult Intelligence Scale (WAIS-III) Digit Symbol Test</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopkins Verbal Learning Test Revised (HVLT)</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Field Sobriety Test</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Back Pain</condition>
  <condition>Neck Pain</condition>
  <arm_group>
    <arm_group_label>Cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose THC, single administration, vaporized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-10 mg oxycodone hydrochloride, single administration, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No active study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <arm_group_label>Cannabis</arm_group_label>
    <other_name>marijuana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <arm_group_label>Oxycodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Cannabis</intervention_name>
    <arm_group_label>Oxycodone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Oxycodone</intervention_name>
    <arm_group_label>Cannabis</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Overall Inclusion Criteria:

          -  Previous smoked or vaporized cannabis exposure

          -  Age â‰¥21 years

        Overall Exclusion Criteria:

          -  Current use of cannabis &gt; once a week

          -  Current substance use disorder

          -  Current alcohol use disorder

          -  Past cannabis abuse/dependence

          -  Current use of amphetamine/methamphetamine, barbiturates, benzodiazepines, cocaine,
             phencyclidine (PCP), MDMA (ecstasy)

          -  Prior adverse reaction to cannabis exposure (paranoia, anxiety, etc.)

          -  Allergy to or prior adverse reaction to oxycodone

          -  Any condition contraindicative to opioid use (e.g. paralytic ileus)

          -  History or diagnosis of serious mental illnesses (e.g., severe depression/anxiety,
             schizophrenia and bipolar disorder)

          -  Current severe depression

          -  Uncontrolled hypertension (&gt;139/89)

          -  Known cardiovascular disease

          -  Chronic pulmonary disease (e.g., bronchitis, asthma, COPD, or emphysema)

          -  History of seizure disorder

          -  Diagnosed inflammatory disease (e.g. Rheumatoid Arthritis (RA))

          -  Cognitive disability that interferes with ability to provide consent or understand
             study procedures

          -  Inability to refrain from using tobacco for at least 4 hours

          -  Pregnant females

          -  Lactating females

        Additional Exclusion Criteria for SPINE PATIENTS

          -  Current regular use of a long acting opioid (e.g. OxyContin, MS Contin, other
             extended release formulas)

          -  Current high-dose use of immediate release opioid (&gt; 45 mg morphine equivalents/day)

          -  Other diagnosed chronic pain syndromes (e.g. fibromyalgia)

        Additional Exclusion Criteria for HEALTHY CONTROLS

          -  Current acute pain

          -  Current chronic pain condition (e.g. fibromyalgia, neuropathy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Lindley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Lindley, PhD</last_name>
    <phone>303-724-0239</phone>
    <email>MJPainStudy@ucdenver.edu</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>September 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Neck Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
